携带致癌融合的转移性未分化肉瘤对拉罗替尼和塞利替尼的反应及耐药机制。（原句似乎不完整，缺少具体的致癌融合相关内容） - Suppr

Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of .

作者信息

Hemming Matthew L, Nathenson Michael J, Lin Jia-Ren, Mei Shaolin, Du Ziming, Malik Karan, Marino-Enriquez Adrian, Jagannathan Jyothi P, Sorger Peter K, Bertagnolli Monica, Sicinska Ewa, Demetri George D, Santagata Sandro

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14.

DOI:10.1200/po.19.00287

PMID:32133433

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7055910/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abd4/7446399/e1a7a3c8d4f9/PO.19.00287f1.jpg

相似文献

Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of .携带致癌融合的转移性未分化肉瘤对拉罗替尼和塞利替尼的反应及耐药机制。（原句似乎不完整，缺少具体的致癌融合相关内容）

JCO Precis Oncol. 2020;4:79-90. doi: 10.1200/po.19.00287. Epub 2020 Feb 14.

Larotrectinib followed by selitrectinib in a novel fusion undifferentiated pleomorphic sarcoma.新型融合未分化多形性肉瘤中先使用拉罗替尼再使用塞利替尼。

J Oncol Pharm Pract. 2021 Mar;27(2):485-489. doi: 10.1177/1078155220938849. Epub 2020 Jul 21.

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal Fusion: Case Report.一名伴有亚克隆融合的肺鳞状非小细胞肺癌患者对拉罗替尼的原发性耐药：病例报告

JTO Clin Res Rep. 2023 Mar 17;4(4):100501. doi: 10.1016/j.jtocrr.2023.100501. eCollection 2023 Apr.

[A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].[1例在单患者扩大准入系统下接受拉罗替尼治疗的伴有LMNA-NTRK1基因融合的小儿软组织肉瘤病例]

Gan To Kagaku Ryoho. 2019 Oct;46(10):1595-1597.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.拉罗替尼治疗携带 NTRK 基因融合的儿科实体瘤：多中心、开放标签、1 期/2 期研究的 1 期结果。

Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.美瑞替尼（LY2801653）可抑制神经营养受体激酶（NTRK），并抑制携带NTRK融合基因的肿瘤生长。

Oncotarget. 2018 Feb 13;9(17):13796-13806. doi: 10.18632/oncotarget.24488. eCollection 2018 Mar 2.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.新辅助拉罗替尼治疗局部晚期 TRK 融合肉瘤儿童患者。

Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.TRK 抑制：一种新的肿瘤不可知治疗策略。

Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.一名软组织肉瘤患者中存在致癌性NTRK融合，对原肌球蛋白相关激酶抑制剂LOXO-101有反应。

Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.拉罗替尼，一种高选择性原肌球蛋白受体激酶（TRK）抑制剂，用于治疗 TRK 融合癌症。

Expert Rev Clin Pharmacol. 2019 Oct;12(10):931-939. doi: 10.1080/17512433.2019.1661775. Epub 2019 Sep 10.

引用本文的文献

Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.多重耐药性：我们还怕那只大坏狼吗？

Pharmaceuticals (Basel). 2025 Jun 14;18(6):895. doi: 10.3390/ph18060895.

Prognostic value of structural variants in early breast cancer patients.早期乳腺癌患者结构变异的预后价值

NPJ Breast Cancer. 2024 Jul 27;10(1):64. doi: 10.1038/s41523-024-00669-9.

Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.通过甲羟戊酸途径诱导神经生长因子 tropomyosin-receptor 激酶抑制剂耐药性与 HMGCS2 有关。

Cancer Med. 2024 Jun;13(12):e7393. doi: 10.1002/cam4.7393.

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.在RET驱动的癌症中，对选择性RET抑制的适应性达尔文脱靶抗性机制。

NPJ Precis Oncol. 2024 Mar 4;8(1):62. doi: 10.1038/s41698-024-00563-4.

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.选择性II型TRK抑制剂克服了xDFG突变介导的对第二代抑制剂塞利替尼和瑞波替尼的获得性耐药。

Acta Pharm Sin B. 2024 Feb;14(2):517-532. doi: 10.1016/j.apsb.2023.11.010. Epub 2023 Nov 8.

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.了解针对非小细胞肺癌的化疗和免疫治疗靶点的可行性：耐药反应及近期联合治疗的最新进展

Explor Target Antitumor Ther. 2023;4(5):850-895. doi: 10.37349/etat.2023.00171. Epub 2023 Oct 10.

Progressive metastatic infantile fibrosarcoma with multiple acquired mutations.进行性转移性婴儿纤维肉瘤，伴有多种获得性突变。

Cold Spring Harb Mol Case Stud. 2023 May 9;9(2). doi: 10.1101/mcs.a006277. Print 2023 Apr.

Salivary gland cancers in elderly patients: challenges and therapeutic strategies.老年患者的唾液腺癌：挑战与治疗策略

Front Oncol. 2022 Nov 25;12:1032471. doi: 10.3389/fonc.2022.1032471. eCollection 2022.

Non-small-cell lung cancer: how to manage - and -rearranged disease.非小细胞肺癌：如何处理ALK重排疾病。

Drugs Context. 2022 Oct 12;11. doi: 10.7573/dic.2022-3-1. eCollection 2022.

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance.非小细胞肺癌中的NTRK融合：诊断、治疗及TRK抑制剂耐药性

Front Oncol. 2022 Mar 17;12:864666. doi: 10.3389/fonc.2022.864666. eCollection 2022.

本文引用的文献

Acquired Resistance Is Oncogene and Drug Agnostic.获得性耐药是癌基因和药物不可知的。

Cancer Cell. 2019 Oct 14;36(4):347-349. doi: 10.1016/j.ccell.2019.09.011.

Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.基于图像的免疫分析和多重组织成像的合格抗体。

Nat Protoc. 2019 Oct;14(10):2900-2930. doi: 10.1038/s41596-019-0206-y. Epub 2019 Sep 18.

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.由汇聚的 MAPK 通路激活介导的 TRK 抑制抗性。

Nat Med. 2019 Sep;25(9):1422-1427. doi: 10.1038/s41591-019-0542-z. Epub 2019 Aug 12.

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.KRAS-IRF2 轴驱动结直肠癌的免疫抑制和免疫治疗耐药性。

Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21.

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.富含高甲基化 MLH1 启动子和野生型 BRAF/KRAS 的结直肠肿瘤富含可靶向的激酶融合。

Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.

NTRK fusion-positive cancers and TRK inhibitor therapy.NTRK 融合阳性癌症和 TRK 抑制剂治疗。

Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0.

Immuno-Oncology: Emerging Targets and Combination Therapies.免疫肿瘤学：新兴靶点与联合疗法

Front Oncol. 2018 Aug 23;8:315. doi: 10.3389/fonc.2018.00315. eCollection 2018.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.Repotrectinib（TPX-0005）是一种下一代 ROS1/TRK/ALK 抑制剂，能够强力抑制 ROS1/TRK/ALK 溶剂前沿突变。

Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9.

Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.免疫组织化学、mRNA 原位杂交检测 PD-L1 表达的一致性水平及其与肺癌预后的关系。

Hum Pathol. 2018 Dec;82:282-288. doi: 10.1016/j.humpath.2018.07.025. Epub 2018 Jul 31.

Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.使用 t-CyCIF 和传统光学显微镜对人组织和肿瘤进行高多重免疫荧光成像。

Elife. 2018 Jul 11;7:e31657. doi: 10.7554/eLife.31657.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of .

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献